Mode
Home Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Digests › Cardiology › 2026-W16
Cardiology 2026-W16 · Published Apr 15, 2026

This Week in Cardiology: SGLT2 Inhibitors and Heart Failure Management

A flurry of research this week focused on the role of SGLT2 inhibitors in heart failure management, particularly in older patients. From the Archives of Gerontology and Geriatrics, a meta-analysis of 20,844 patients aged 65+ found that SGLT2 inhibitors were associated with reduced all-cause mortality (HR 0.81) and heart failure hospitalization (HR 0.73) [1].

The analysis pooled data from 10 studies, including both randomized trials and observational cohorts, suggesting these medications may be a valuable consideration for older HF patients. Meanwhile, JAMA Internal Medicine reported on a secondary analysis of a phase 3b trial evaluating oral semaglutide in patients with type 2 diabetes and heart failure history [2].

While the study found no overall benefit for cardiovascular risk reduction, there was a significant reduction in composite heart failure outcomes specifically among participants with baseline heart failure. This suggests potential benefits for those with established heart failure, though further research is needed to confirm broader cardiovascular risk reduction.

Articles in This Digest

Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients Older Adults With Heart Failure May Gain Years From This Pill
A systematic review and meta-analysis of 20,844 patients aged 65+ with heart failure found SGLT2 inhibitors were associated with reduced all-cause mortality (HR…
A pooled look at 10 studies in over 20,000 older adults shows SGLT2 inhibitors cut the risk of dying from any cause by about a fifth — and the benefit shows up …
Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history. A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants with type 2 diabetes …
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-one benefit.
Antihypertensive therapy in mild hypertension may not reduce mortality or cardiovascular events compared to placebo. Your Blood Pressure Pills May Not Be Doing What You Think
This Cochrane systematic review update analyzed data from 9,124 adults with untreated mild hypertension and no pre-existing cardiovascular disease. The meta-ana…
A major medical review found blood pressure pills for mild cases may not prevent death or heart attacks while causing side effects that make nearly five times m…
Adding low-dose rivaroxaban to DAPT did not significantly reduce LV thrombus in anterior STEMI patients. Adding low-dose rivaroxaban to standard heart attack drugs did not clearly prevent blood clots in the heart
This randomized clinical trial evaluated 560 patients with anterior ST-segment elevation myocardial infarction (STEMI) across 29 centers in France. Participants…
Adding a low-dose blood thinner to standard heart attack drugs did not clearly prevent dangerous clots in the heart, based on a trial of 560 patients.
Ticagrelor Not Noninferior to Prasugrel in Diabetes Patients With Multivessel CAD After PCI New study shows ticagrelor did not beat prasugrel for heart attack prevention in diabetics
This randomized clinical trial of 1,800 patients with diabetes and multivessel coronary artery disease undergoing PCI compared ticagrelor plus aspirin to prasug…
For diabetics with heart stents, a new study found ticagrelor offered no clear advantage over prasugrel in preventing death, heart attacks, or strokes.
← 2026-W14 All Cardiology digests → 2026-W17 →